Back to news

Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer

Globe Newswire•16/11/2026•02:00 ET
0

Key Highlights

  • ➤Relmada (RLMD) appoints Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology
  • ➤Jakobsen will lead clinical development, including planned Phase 3 SPECTRUM program for NDV-01
  • ➤Jakobsen led pivotal ADSTILADRIN development at Ferring through FDA and global approvals
  • ➤NDV-01 Phase 2 results showed high, durable complete response rates and favorable safety
  • ➤NDV-01 is planned for convenient in-office administration using a ready-to-use product

Expert Statements

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“I am delighted to welcome Jørn to Relmada as we enter a critical phase in the development of NDV-01”

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“Jørn has treated patients with bladder cancer and led the pivotal development program for ADSTILADRIN, the first intravesical gene therapy approved globally by the FDA, EMA, PMDA, and Health Canada for the treatment of NMIBC.”

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“His experience navigating global regulatory authorities and guiding clinical strategy will be invaluable as we prepare to initiate the SPECTRUM registrational Phase 3 program.”

Sergio Traversa, Chief Executive Officer of Relmada Therapeutics

“We are building a development organization with the leadership required to realize the full potential of NDV-01, and I am thrilled to have Jørn helping lead that effort.”

Jørn Skibsted Jakobsen, MD, PhD, Chief Development Officer, Urology & Uro-Oncology, of Relmada Therapeutics

“I am excited to join Relmada because I believe NDV-01 has the potential to transform how we treat patients with NMIBC.”

Jørn Skibsted Jakobsen, MD, PhD, Chief Development Officer, Urology & Uro-Oncology, of Relmada Therapeutics

“The Phase 2 results for NDV-01 are compelling, demonstrating high, durable complete response rates alongside favorable safety and tolerability.”

Jørn Skibsted Jakobsen, MD, PhD, Chief Development Officer, Urology & Uro-Oncology, of Relmada Therapeutics

“Equally important is the potential to offer a therapy that fits seamlessly into everyday urology practice through convenient in-office administration with a ready-to-use product.”

Jørn Skibsted Jakobsen, MD, PhD, Chief Development Officer, Urology & Uro-Oncology, of Relmada Therapeutics

“I look forward to collaborating with the Relmada team to advance NDV-01 through the SPECTRUM program and bring this important new treatment option to patients with NMIBC.”

CORAL GABLES, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology. Dr. Jakobsen will lead clinical development across Relmada’s pipeline, including the planned Phase 3 SPECTRUM registrational program for NDV-01.

Dr. Jakobsen is an accomplished clinical development executive and board-certified urologist who served as the Head of Global Clinical Development for the pivotal program of Ferring Pharmaceuticals’ ADSTILADRIN(®) that culminated in approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and Health Canada for the treatment of non-muscle invasive bladder cancer (NMIBC). During his nine-year tenure at Ferring Pharmaceuticals, he led the company’s urology and uro-oncology therapeutic area, overseeing global clinical development strategy, registrational studies, and regulatory interactions. He also directed the lifecycle expansion of ADSTILADRIN’s clinical program into additional patient populations.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in